

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043452 A1

(51) International Patent Classification⁷: **A61K 31/198**,
A61P 5/14

(21) International Application Number:
PCT/EP2003/012584

(22) International Filing Date:
11 November 2003 (11.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2002A002394
13 November 2002 (13.11.2002) IT

(71) Applicant (for all designated States except US): **BRACCO**
S.p.A. [IT/IT]; Via Egidio Folli, 50, I-20134 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PINCHERA**, Aldo
[IT/IT]; Bracco S.p.A., Via Egidio Folli, 50, I-20134 Mi-
lano (IT). **SANTINI**, Ferruccio [IT/IT]; Bracco S.p.A.,
Via Egidio Folli, 50, I-20134 Milano (IT).

(74) Agent: **MACCHETTA**, Francesco; Bracco S.p.A., Intel-
lectual Property Department, Via Egidio Folli, 50, I-20134
Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent
(BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: 3,5,3'-TRIODOXYTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULA-
TIONS THEREOF

(57) Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T₃S, as a medicament having thy-
romimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T₃), as such or in association
with thyroxine (T₄), and pharmaceutical formulations thereof.

3,5,3'-TRIIODOTHYRONINE SULFATE AS THYROMIMETIC AGENT AND PHARMACEUTICAL FORMULATIONS THEREOF

FIELD OF THE INVENTION

The present invention regards the use of 3,5,3'-triiodothyronine sulfate, usually named triiodothyronine sulfate or T_3 sulfate or even better T_3S , as an active principle, alone or in combination with thyroxine, in the treatment of pathologies due to organic deficiency of 3,5,3'-triiodothyronine. Accordingly, the same is usable for the preparation of thyromimetic pharmaceutical compositions.

BACKGROUND OF THE INVENTION

A number of iodothyronines are present in blood, which are directly produced by thyroid gland or are the result of peripheral metabolism of other iodothyronines. Among them, 3,5,3'-triiodothyronine (acronym T_3) is deemed to be the biological active form of thyroid hormone (TH), because it has shown high affinity for the specific receptors of the same and is normally present in serum at a concentration sufficient for the activation of said receptors.

The main secretion product of thyroid gland in the healthy adult is thyroxine, commonly designated with the acronym T_4 . It is peripherically converted to its biologically active form, T_3 (Ref.1), through enzymatic removal of an iodine atom from the external aromatic ring of the molecule by both type I and type II 5'-iodothyronine monodeiodinases (type I MD and type II MD, respectively). This metabolic pathway is the main mechanism of endogenous production of T_3 ; on consequence, T_4 can properly be considered a pro-hormone. On the other hand, a minor part of

T_3 is also directly secreted by thyroid. On average, the amount of T_4 produced in an adult being of 70 Kg weight every day amounts to 100 μg , while the total production of T_3 amounts to around 25 μg . 4-8 μg of T_3 out of said 25 μg are directly secreted by thyroid and the remaining ones
5 derive from the peripheral conversion of T_4 .

T_3 undergoes two different metabolic pathways. The main metabolic pathway consists in the partial deiodination of the inner aromatic ring by type III 5-iodothyronine monodeiodinase (type III MD) to give 3,3'-diiodothyronine, which is biologically non-active and is further
10 metabolized through deiodination or sulfoconjugation. The other metabolic pathway regards around 20% of the total amount of T_3 produced by the body and brings on sulfoconjugation of T_3 to give $T_3\text{S}$, which is not able to bond to the thyroid hormones (Ref.2), thus resulting biologically non-active (Ref.3).

15 Contrary to what happens with T_3 , $T_3\text{S}$ is not deiodinated by type III MD. Rather, it resulted to be an excellent substrate for type I MD (Ref.4), which converts it very quickly into 3,3'-diiodothyronine sulphate. On consequence it has been widespread common knowledge that, in the healthy adult being, sulfoconjugation of T_3 to give $T_3\text{S}$ represents a way
20 for speeding up the catabolism of T_3 , so facilitating its biliary and urinary excretion. Actually, it was found that serum levels of $T_3\text{S}$, physiologically low in the health adult, are higher when type I MD activity is reduced.

Yet, it has also unexpectedly been found that, just in some body districts and organs, sulfatases exist which, under particular physiological
25 conditions and situations, are able to convert again $T_3\text{S}$ into its active form T_3 (Ref's.7-9).

Such enzymes have been described in the intestinal microflora as well

as in body tissues like liver, kidneys and nervous central system (Ref.10).

Recently, it has been found that endogenous T_3S levels in serum are quite high during intrauterine life and as such are kept by the body, i.e. higher than the ones normally found in the adult being, at least until the
5 forth month of postnatal life (Ref.11). Considering the essential role played by thyroid hormones during growth, in particular as far as nervous central system functions are involved, suppositions have been made about the possibility that, in this tissue, T_3S may also possibly be used by the body as an occasional source of T_3 , if and when needed, during the first period of
10 life. Studies performed on autoptic specimens of human nervous cerebral tissue post-mortem showed that the amount of T_3 in the same results limited by **type III MD** (Ref.12). While this enzyme does not attack T_3S , it has been surmised that T_3S may exceptionally represent an alternative endogenous source of T_3 hormone in those tissues which contain sulfatases
15 able to reconvert T_3S into its active form, just in case a particular need of the hormone arises in said tissues (Ref's.8, 13).

Further studies have been performed to ascertain the effective role played by T_3S during production and metabolism of thyroid hormones. Said studies have recently demonstrated that it shows thyromimetic effects
20 in hypothyroid rats (Ref.10) as well as in euthyroid rats (Ref.14). In both cases T_3S has shown a potency of around one fifth that of T_3 . Moreover both treatments with T_3S and with T_3 produced a significant reduction of serum levels of thyreotropic hormone (**TSH**) in euthyroid rats, thus showing to possess similar capability in inhibiting its secretion. On the
25 contrary, in the case of hypothyroid rats, T_3S showed a poor capability of inhibiting **TSH** secretion when compared to T_3 . It is well known that **TSH** is a highly responsive indicator to the functional status of thyroid gland

and consents to detect the smallest alterations of its hormonal secretion. Actually, its levels are higher under conditions of reduced thyroid functionality, even in those conditions that are defined as sub-clinical, while they are reduced when an excess of thyroid hormones are present.

5 Accordingly, T_3S seems unexpectedly non-comparable to T_3 as far as its capability of inhibition on formation of TSH is involved.

In conclusion, particularly in view of the latest studies, a clear and complete knowledge of the biological role played by T_3S has not yet been reached.

10 In fact its main, well-grounded and universally accepted, feature is its non-biological activity, i.e. it is a biologically inert metabolite of T_3 (Ref's.2 and 3), and the sulfation pathway is regarded as a metabolic activator of T_3 catabolism (Ref.5).

15 On the other hand, only in particular tissues and under exceptional critical conditions due to shortage of thyroid hormone in those tissues, it has been shown its potential as an endogenous local source of T_3 .

20 As a result, today the skilled technician is still facing a complex, somewhat conflicting, situation, which highlights only some of the biological characteristics of the product and needs more exhaustive in depth studies.

25 In any case, none of the several documents forming the state-of-the-art discloses, shows or suggests the possibility of using this anomalous metabolite of T_3 in therapy. No close prior-art document, either of experimental nature or substantially speculative, either taken alone or in combination with other related documents, suggests the use, or even the potential use of T_3S as a medicament, taken as such or

preferably in combination with other thyroid hormones or pro-hormones, like, for example T_4 . The fact that, only in some specific tissues of the body and under particular, peculiar circumstances, part of T_3S can be reconverted into T_3 does not mean, nor implies, nor suggests that it is possible to generalize this feature to the whole organism through exogenous administration of the product. In particular, there is no suggestion that oral administration of the product, even in protected form according to known methods of the pharmaceutical technique, may render it bioavailable also because it is well known that in those districts where suitable sulfatases are not present the same is rapidly metabolized and excreted through the bile and urines.

SUMMARY OF THE INVENTION

It has now unexpectedly been found, and this is one of the aspects of the present invention, that T_3S , as such or in association with other thyroid hormones or pro-hormones, preferably T_4 , and properly formulated according to the desired application, is particularly useful as a medicament to be used in all those pathologies caused by insufficient production by the body of the needed quantities of active thyroid hormones, in particular T_3 .

DETAILED DESCRIPTION OF THE INVENTION

In fact, it has unexpectedly been found that the administration of T_3S , contrary to what known about its normal metabolism, allows to maintain steady levels of T_3 in the body for long times (from 12 to 18 hrs) and that results particularly useful in those cases in which it is needed to supplement thyroid hormone in its most active form.

Particularly preferred in the therapy of hypothyroidism, and this is a main aspects of the present invention, is resulted the association of T_3S with T_4 . The hormonal association which, in theory, should more accurately mime the normal thyroid secretion is represented by a combination of T_4 with T_3 . Actually, pharmaceutical compositions comprising both of said iodothyronines, formulated in proportions similar to the ones of the normal physiologic secretion, have already been tried and marketed. Unfortunately, the oral simultaneous administration of T_4 with T_3 was not able to reproduce the normal thyroid hormones serum levels, because of pharmacokinetics of T_3 . In fact, T_3 undergoes a very quick absorption and an equally quick elimination after oral administration; its elimination rate is about 20 times higher than the one of T_4 . For this reason administration of T_3 gives raise to a dangerous peak excess in hormone concentration, if compared to the normal physiologic levels, followed by a too much fast drop to sub-physiologic levels. On consequence, today most of the specialised physicians prefer using T_4 alone, even if in this way production of T_3 only depends on the periferic deiodination of T_4 , because direct secretion of T_3 by thyroid does not exists or is seriously insufficient.

On the contrary, the association of the invention avoids the above problems, because it has unexpectedly been found that, for example, after oral administration, T_3S provides T_3 serum levels that increase in a gradual way and keep steady for long periods of time, thus preventing the formation of too much high peaks.

Another unexpected advantage deriving from the use of T_3S in the treatment of pathologies due to organic deficiency of T_3 consists in its recently found systemic thyromimetic activity linked to a poor inhibition of

TSH secretion. This effect is particularly useful in the case of thyroidectomized patients suffering from thyroid carcinoma, when administration of T_4 must be suspended in view of carrying out total body scintigraphy. In such a case administration of T_3S instead of T_4 may solve
5 patient's necessity, without interfering with the diagnostic examination.

Another further advantage of T_3S in the therapy of hypothyroidism regards its autolimitation capability. In fact, it is actively deiodinated by **type I MD**, which, on its part, is stimulated by thyroid hormones. In hypothyroid subjects **type I MD** activity is reduced; on consequence also
10 T_3S elimination is slowed. As a matter of fact, its effect on the body results greater. On the contrary, in case of over administration, **type I MD** activity is increased, thus giving more T_3S elimination, i.e. limiting possible undesired collateral effects.

Last but not least, a further advantage of T_3S is represented by the
15 fact that it is a metabolite normally present in the body, usually non-active, i.e. non-toxic. On consequence problems of hypersensitivity or intolerance following its administration are not reasonably predictable.

Accordingly, another main aspect of the present invention regards pharmaceutical formulations comprising T_3S as an active principle, as such
20 or in combination with other thyroid hormones or pro-hormones. Particularly preferred are formulations comprising T_3S in association with T_4 .

Said formulations differ in the dosage of the active principle or principles, or in the type of pharmaceutical form provided, depending on
25 the desired administration kind. Moreover they can also contain useful additives like excipients, diluents, dissolvents, solvents, carriers, dyestuffs, flavourings, sweeteners commonly used in the pharmaceutical technology.

The preparation of specific pharmaceutical formulations in response to particular needs of administration is plainly comprised in the general technical field of the present invention.

5 **EXPERIMENTAL SECTION**

As an example, absolutely non-limiting for the skilled technician, T₃S may be administered for oral use at doses ranging from 5 to 1000 µg, preferably from 10 to 500 µg, more preferably from 25 to 250 µg.

10 Analogously, when in association with T₄, preferred doses range from 10 to 500 µg for T₃S and from 10 to 250 µg for T₄, more preferably from 25 to 250 µg for T₃S and from 25 to 200 µg for T₄.

Two representative formulations for oral administration, selected among the preferred ones, are hereinafter enclosed by way of an example. Obviously, said formulations have no limiting effect on the
15 other possible variations, which may also comprise different types of administration, different doses or different components depending on the specific pharmacological application or the particular pathology.

Example A) – Oral formulation containing T₃S

20	T₃S	50	µg;
	Calcium phosphate dibasic anhydrous	103.5	mg;
	Mais starch	17.65	mg;
	Microcrystalline cellulose	5	mg;
	Sodium carboxymethylamide	5	mg;
25	Talc	5	mg;
	Citric acid	2.8	mg;
	Magnesium stearate	1	mg

Example B) – Oral formulation containing T₃S and T₄

	T₃S	50	µg;
	T₄ sodium salt	125	µg;
	Calcium phosphate dibasic anhydrous	103.5	mg;
5	Mais starch	17.525	mg;
	Microcrystalline cellulose	5	mg;
	Sodium carboxymethylamide	5	mg;
	Talc	5	mg;
	Citric acid	2.8	mg;
10	Magnesium stearate	1	mg

In particular, when the association is taken into account, the formulations of the present invention will also possibly comprise individually formulated doses of T₃S and T₄, so that sequential
15 administration is possible. In this case, one suitable kit is provided, which consents distinct administration of said active principles in ways that can differ from patient to patient, depending on the needed therapeutic application. In such a way, the specialized physician will have a wide choice of changing the prescription according to the
20 actual need of the patient.

Just by way of an absolutely non-limitative example, in the case of oral administration, one package containing two individual blisters, which have different shape and/or color and/or different contents and/or doses, may suit the desired scope. Other possibilities exist and
25 are easily available to the expert of the field.

The pharmaceutical compositions of the present invention are usable in the treatment of pathologies due to organic deficiency of

triiodothyronine (T_3), like, for example, original hypothyroidism from autoimmune thyroid affections, hormonal production defects, thyroidectomy, congenital hypothyroidism, as well as some disorders due to reduced activity of type I 5'-iodothyronine monodeiodinase (**type I MD**)
5 which is induced, for example, by hypothyroidism, non thyroidal systemic illnesses, fast, selenium shortage and so on.

REFERENCES

1. Chopra IJ. Nature, source and relative biological significance of
5 circulating thyroid hormones. In: Braverman LE., Utiger RD. (eds) The
Thyroid, Lippincott, Philadelphia 1991, pp. 126-143.
2. Spaulding SW., Smith TJ., Hinkle PM., Davis FB., Kung MP., Roth
JA. Studies on the biological activity of triiodothyronine sulfate.
J.Clin.Endocrinol.Metab. 1992, 74, 1062-1067.
- 10 3. Lo Presti JS., Mizuno L., Nimalysuria A., Anderson KP., Spencer
CA., Nicoloff JT. Characteristics of 3,5,3'-triiodothyronine sulfate
metabolism in euthyroid man. J.Clin.Endocrinol.Metab. 1991, 73, 703-709.
4. Santini F., Hurd RE., Chopra IJ. A study of metabolism of
deaminated and sulfoconjugated iodothyronines by rat placental
15 iodothyronine 5-monodeiodinase. Endocrinology 1992, 131, No.4, 1689-
1694.
5. Otten MH., Mol JA., Visser TJ. Sulfation preceding deiodination of
iodothyronines in rat hepatocytes. Science 1983, 221, 81-83.
6. Mol JA., Visser TJ. Rapid and selective inner ring deiodination of T₄
20 sulfate by rat liver deiodinase. Endocrinology 1986, 117, 8-12.
7. Kung MP., Spaulding SW., Roth JA. Desulfation of 3,5,3'-
triiodothyronine sulfate by microsomes from human and rat tissues.
Endocrinology 1988, 122, 1195-1200.
8. Santini F., Chopra IJ., Wu SY., Solomon DH., Chua Teco GN.
25 Metabolism of 3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: a
consideration of the role of desulfation of 3,5,3'-triiodothyronine sulfate as
a source of T₃. Pediatr.Res. 1992, 31, 541-544.
9. De Herder WW., Hazenberg MP., Pennock-Schroeder AM.,
Hennemann G., Visser TJ. Rapid bacteria-dependent *in vitro* hydrolysis of

iodothyronine conjugates by intestinal contents of humans and rats. Med.Biol. 1986, **64**, 31-35.

10. Santini F., Hurd RE., Lee B., Chopra IJ. Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats. Endocrinology 1993, **133**, No.1, 105-110.
5
11. Santini F., Chiovato L., Ghiri P., Lapi P., Mammoli C., Montanelli L., Scartabelli G., Ceccarini G., Coccoli L., Chopra IJ., Boldrini A., Pinchera A. Serum iodothyronines in human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. J.Cl.Endocrinol.Metab. 1999, **84**, No.2, 493-498.
10
12. Santini F., Pinchera A., Ceccarini G., Castagna M., Rosellini V., Mammoli C., Montanelli L., Zucchi V., Chopra IJ., Chiovato L. Evidence for the role of the type III-iodothyronine deiodinase in the regulation of 3,5,3'-triiodothyronine content in the human central nervous system. Eur.J.Endocrinol. 2001, **144**, 577-583.
15
13. Santini F., Cortellazzi D., Baggiani AM., Marconi AM., Beck-Peccoz P., Chopra IJ. A study of the serum 3,5,3'-triiodothyronine sulfate concentration in normal and hypothyroid fetuses at various gestational stages. J.Cl.Endocrinol.Metab. 1993, **76**, No.6, 1583-1587.
- 20 14. Chopra IJ., Nguyen D. Demonstration of thyromimetic effects of 3,5,3'-triiodothyronine sulfate (T₃S) in Euthyroid rats. Thyroid 1996, **6**, No.3, 229-232.

CLAIMS

1. Triiodothyronine sulfate for use as a medicament.
2. Triiodothyronine sulphate for use as a medicament according to
5 claim 1, having thyromimetic activity.
3. Triiodothyronine sulfate according to claim 2, for use in the treatment of pathologies due to organic deficiency of triiodothyronine.
4. Triiodothyronine sulfate according to claim 3, wherein said pathologies comprise original hypothyroidism from autoimmune thyroid
10 affections, hormonal production defects, thyroidectomy, congenital hypothyroidism.
5. Triiodothyronine sulfate according to claim 2, for use in the treatment of disorders due to reduced activity of type I 5'-iodothyronine monodeiodinase.
- 15 6. Triiodothyronine sulfate according to claim 5, wherein said reduced activity of type I 5'-iodothyronine monodeiodinase comprises, among its grounds, hypothyroidism, non thyroidal systemic illnesses, fast, selenium shortage.
7. Pharmaceutical compositions comprising triiodothyronine sulfate as
20 an active principle.
8. Pharmaceutical compositions according to claim 7, wherein said triiodothyronine sulfate is formulated in association with thyroxine.
9. Pharmaceutical compositions according to claim 7 and 8, wherein said compositions further comprise additives like excipients, diluents,
25 dissolvents, solvents, carriers, dyestuffs, flavourings, sweeteners.
10. Pharmaceutical compositions according to claim 7, wherein triiodothyronine sulfate is administered at doses ranging from 5 to 1000 µg.

11. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses ranging from 10 to 500 μg .
12. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses ranging from 25 to 250 μg .
- 5 13. Pharmaceutical compositions according to claim 8, wherein said association is administered at doses ranging from 10 to 500 μg of triiodothyronine sulfate and from 10 to 250 μg of thyroxine.
14. Pharmaceutical compositions according to claim 8, wherein said association is administered at doses ranging from 25 to 250 μg of
10 triiodothyronine sulfate and from 25 to 200 μg of thyroxine.
15. Kit for the differential or sequential administration of the pharmaceutical compositions according to claims 8, 9 and 11 to 14.
16. Use of triiodothyronine sulfate for the preparation of the pharmaceutical compositions according to claims 7 to 15.

INTERNATIONAL SEARCH REPORT

International Publication No
PCT/EP 03/12584

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/198 A61P5/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SANTINI FERRUCCIO ET AL: "Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats" ENDOCRINOLOGY, vol. 133, no. 1, 1993, pages 105-110, XP002272821 ISSN: 0013-7227 cited in the application page 108, column 2, paragraph 1 page 109, column 1, paragraph 2 ---</p> <p style="text-align: center;">-/--</p>	1-16

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

9 March 2004

Date of mailing of the international search report

25/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Büttner, U

INTERNATIONAL SEARCH REPORT

International Publication No.

PCT/EP 03/12584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHOPRA I J ET AL: "Demonstration of thyromimetic effects of 3,5,3'-triiodothyronine sulfate (T3S) in euthyroid rats"</p> <p>THYROID 1996 UNITED STATES, vol. 6, no. 3, 1996, pages 229-232, XP009027310</p> <p>ISSN: 1050-7256</p> <p>cited in the application</p> <p>abstract</p> <p>page 230, column 2, paragraph 2</p> <p>page 231, column 1, paragraph 2</p> <p>-----</p>	1-16